• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    CBD Life Sciences, Inc. (CBDL) Launches First-of-Its-Kind CBD Horse Paste: A Veterinarian-Designed Solution for Equine Wellness

    10/3/24 8:00:00 AM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary
    Get the next $YCBD alert in real time by email

    The annual economic impact of the equine industry is significant - involving some $300 billion dollars and 1.6 million full-time jobs. CBD Life Sciences' Groundbreaking Horse Paste is Set to Transform the Industry and Drive Explosive Growth

    SCOTTSDALE, AZ / ACCESSWIRE / October 3, 2024 / CBD Life Sciences, Inc. (CBDL), an industry leader in innovative CBD solutions, proudly announces the launch of its latest product, the CBD Horse Paste. This veterinarian-designed formulation is the first of its kind, offering unparalleled support for horses facing both physical and psychological challenges.

    A Game-Changer in the Equine Wellness Market

    Equine health concerns such as muscle stiffness, joint pain, and anxiety can significantly affect a horse's well-being. The CBD Horse Paste addresses these issues with a unique combination of cannabinoids and terpenes, providing an easy-to-administer solution that stays in the horse's mouth longer than CBD oils, ensuring maximum absorption. Each syringe delivers 500mg of premium CBD with a flavor horses love, making it ideal for stress-inducing situations like farrier visits or long trailer rides.

    "By creating the CBD Horse Paste, we are revolutionizing equine wellness with a product that not only relieves physical discomfort but also calms behavioral issues. This is the first solution of its kind in the market, and we believe it has the potential to transform the industry," said Lisa Nelson, President and CEO of CBD Life Sciences, Inc.

    Positioned for Explosive Growth

    With the global CBD market projected to reach $47.22 billion by 2028, CBD Life Sciences, Inc. is well-positioned to capitalize on this momentum. The equine health sector represents an untapped market poised for rapid expansion. As horse owners seek natural, effective alternatives to traditional medications, the CBD Horse Paste is primed to become a must-have solution for equine care.

    CBDL has already experienced remarkable growth in 2024, with a 1405.46% revenue increase since February. The introduction of this breakthrough product is expected to further accelerate the company's upward trajectory, potentially opening doors to new markets and increasing its share in the fast-growing CBD industry. Analysts predict that the equine CBD market alone could see multi-million-dollar growth in the coming years, making the CBD Horse Paste a key driver for CBDL's future success.

    Key Benefits of CBD Horse Paste

    • Veterinarian-Designed Formulation: Created by equine health experts for maximum effectiveness.

    • Comprehensive Health Support: Eases muscle stiffness, joint issues, and stress-related behaviors like boredom and anxiety

    • Easy-to-Use: Each syringe contains four doses, making it convenient for horse owners

    • Delicious Flavor: The paste's flavor ensures horses readily accept it.

    • Versatile Application: Perfect for use during stressful situations, such as travel, farrier visits, and training sessions

    Innovative CBD for Equine Wellness

    The CBD Horse Paste not only addresses common equine health concerns but also serves as a natural alternative to traditional calming agents and medications. By leveraging the powerful properties of CBD and terpenes, horses can experience relief from arthritis-induced stiffness and joint pain, as well as a reduction in anxiety caused by environmental changes, isolation, or past trauma.

    A Bright Future for CBDL

    With products like the CBD Horse Paste, CBD Life Sciences, Inc. continues to position itself as a leader in the animal health space. By tapping into the multi-billion-dollar CBD industry and expanding its equine product line, CBDL is set to capture new market segments and drive sustained revenue growth.

    Follow our social media for the latest updates!

    X: https://www.x.com/CBDL_StockOTC
    Instagram: https://www.instagram.com/cbd.vault
    IR Contact: [email protected]

    Forward-Looking Statements
    Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

    Safe Harbor Statement
    This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.

    Contact Information
    Lisa Nelson
    CEO
    [email protected]
    4802091720

    Related Images

    SOURCE: CBD Life Sciences Inc.



    View the original press release on accesswire.com

    Get the next $YCBD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $YCBD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $YCBD
    SEC Filings

    View All

    SEC Form PRE 14A filed by cbdMD Inc.

    PRE 14A - cbdMD, Inc. (0001644903) (Filer)

    1/30/26 8:22:40 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form S-1 filed by cbdMD Inc.

    S-1 - cbdMD, Inc. (0001644903) (Filer)

    1/22/26 9:14:20 AM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    Amendment: SEC Form 10-K/A filed by cbdMD Inc.

    10-K/A - cbdMD, Inc. (0001644903) (Filer)

    1/20/26 4:05:38 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    $YCBD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Crosnoe Clark R. sold $1,276,842 worth of shares (550,701 units at $2.32) (SEC Form 4)

    4 - cbdMD, Inc. (0001644903) (Issuer)

    12/19/25 9:16:26 AM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    CEO and CFO Kennedy Thomas Ronan was granted 445,000 shares, increasing direct ownership by 648% to 513,722 units (SEC Form 4)

    4 - cbdMD, Inc. (0001644903) (Issuer)

    12/2/25 6:29:31 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    Director Porter Jeffrey H was granted 1,572 shares (SEC Form 4)

    4 - cbdMD, Inc. (0001644903) (Issuer)

    5/20/25 5:23:40 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    $YCBD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    cbdMD, Inc. to Host Conference Call to Discuss December 31, 2025 First Quarter Results

    CHARLOTTE, N.C., Feb. 12, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE:YCBD), one of the nation's leading, highly trusted and widely recognized CBD companies, today announces that it will host a conference call at 4:20 p.m., Eastern Time, on Tuesday, February 17, 2026, to discuss the company's December 31, 2025 first quarter financial results and business progress. CONFERENCE CALL DETAILS Tuesday, February 17, 2026, 4:20 p.m. Eastern Time USA/Canada: 888-880-3330 Webcast/Webcast Replay link - available through February 17, 2027: https://app.webinar.net/YzX7D4ynvN2 About cbdMD, Inc.

    2/12/26 5:31:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    cbdMD's Herbal Oasis Expands into Louisiana with Morales Beverage Group Following Strong Texas Momentum

    CHARLOTTE, N.C., Feb. 2, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE:YCBD), a leading innovator in wellness and hemp-derived consumer products, today announced a major distribution expansion for its Herbal Oasis THC-infused social seltzer ("Oasis") through an expanded partnership with Morales Beverage Group ("MBG"). The agreement extends Oasis into Louisiana, strengthening the brand's regional footprint across the Gulf South and creating a more contiguous platform for continued Southeast growth, following strong early performance in Texas. With MBG's established statewide distribut

    2/2/26 9:00:00 AM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    cbdMD Strengthens Regulatory Science Platform to Support Emerging Regulatory Cannabinoid Evaluation Pathways

    CHARLOTTE, N.C., Jan. 29, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE:YCBD), a leading innovator in hemp-derived wellness products, today announced a strategic initiative to integrate and expand its regulatory science, safety, and intellectual property assets to establish a differentiated cannabinoid compliance and evidence platform aligned with evolving federal healthcare evaluation frameworks, including emerging CMS and CMMI innovation initiatives. The program combines scientific and regulatory assets acquired through cbdMD's recent acquisition of Bluebird Botanicals ("Bluebird")

    1/29/26 12:53:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    $YCBD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald resumed coverage on cbdMD with a new price target

    Cantor Fitzgerald resumed coverage of cbdMD with a rating of Neutral and set a new price target of $3.25 from $4.10 previously

    6/18/21 6:26:36 AM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    Cantor Fitzgerald reiterated coverage on cbdMD with a new price target

    Cantor Fitzgerald reiterated coverage of cbdMD with a rating of Neutral and set a new price target of $4.30 from $3.60 previously

    1/29/21 4:54:10 AM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    $YCBD
    Leadership Updates

    Live Leadership Updates

    View All

    cbdMD, Inc. Announces Shareholder Approval of Automatic Conversion of Series A Preferred Stock and Other Results from Annual Meeting

    Charlotte, North Carolina--(Newsfile Corp. - April 10, 2025) - cbdMD, Inc. (NYSE:YCBD) (NYSE:YCBDPA) (the "Company" or "cbdMD") one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD and Paw CBD, along with its functional mushroom brand ATRx Labs and emerging THC-infused seltzer brand Herbal Oasis announced today that at the Company's annual meeting of shareholders held on April 10, 2025, that its Common Stock holders and 8% Series A Cumulative Convertible Preferred Stock (the "Preferred Stock") holders approved the automatic conversion (the "Conversion") of shares of the Company's Preferred Stock into shares of the Comp

    4/10/25 5:57:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    cbdMD Announces Partnership with Medical Advisor, Dr. Lucille Vega

    Charlotte, North Carolina--(Newsfile Corp. - June 22, 2023) - cbdMD (NYSE:YCBD), one of the nation's leading providers of premium cannabidiol (CBD) products, is delighted to announce the appointment of Dr. Lucille Vega as their new medical advisor. This collaboration marks an exciting chapter for both parties, as they play a pivotal role in educating the public about the numerous benefits of CBD and cbdMD's commitment to quality and transparency.As a brand that's renowned for its commitment to quality and innovation, cbdMD's comprehensive line of products spans across various categories and caters to a diverse range of consumer needs. By partnering with Dr. Vega, a highly qualified and passi

    6/22/23 9:00:00 AM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    cbdMD Welcomes Shannon Charles as Chief Marketing Officer

    Charlotte, North Carolina--(Newsfile Corp. - January 11, 2023) - cbdMD, Inc. (NYSE:YCBD) (NYSE:YCBDPA), one of the nation's leading, highly trusted and widely recognized CBD companies, today announces the appointment of Shannon Charles as Chief Marketing Officer. Shannon is a veteran in health and wellness with over a decade of success in the Natural Product Industry. She has a proven record in driving growth across B&M retail, warehouse club stores, ecommerce, as well as international markets. Shannon's leadership has supported the successful brand stories of Naturade, NeoCell, and NutraNext, which the latter was ultimately acquired by The Clorox Co during her tenure. "We are thrilled to h

    1/11/23 12:33:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    $YCBD
    Financials

    Live finance-specific insights

    View All

    cbdMD, Inc. to Host Conference Call to Discuss December 31, 2025 First Quarter Results

    CHARLOTTE, N.C., Feb. 12, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE:YCBD), one of the nation's leading, highly trusted and widely recognized CBD companies, today announces that it will host a conference call at 4:20 p.m., Eastern Time, on Tuesday, February 17, 2026, to discuss the company's December 31, 2025 first quarter financial results and business progress. CONFERENCE CALL DETAILS Tuesday, February 17, 2026, 4:20 p.m. Eastern Time USA/Canada: 888-880-3330 Webcast/Webcast Replay link - available through February 17, 2027: https://app.webinar.net/YzX7D4ynvN2 About cbdMD, Inc.

    2/12/26 5:31:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    cbdMD Reports Third Consecutive Year of Operating Improvement, Strengthens Balance Sheet, and Regains NYSE American Continued Listing Compliance

    CHARLOTTE, N.C., Dec. 19, 2025 /PRNewswire/ -- cbdMD, Inc. (NYSE:YCBD), one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD and Paw CBD, along with hemp derived THC beverage line Herbal Oasis today announced our financial results for the full fiscal year ended September 30, 2025. For fiscal year 2025, cbdMD delivered its third consecutive year of operational and financial improvement, reflecting disciplined cost management, focused execution, and continued investment in quality and science. The Company

    12/19/25 4:10:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    cbdMD, Inc. to Host Conference Call to Discuss September 30, 2025, Fourth Quarter and Fiscal Year 2025 Results

    CHARLOTTE, N.C., Dec. 17, 2025 /PRNewswire/ -- cbdMD, Inc. (NYSE:YCBD), one of the nation's leading, highly trusted and widely recognized CBD companies, today announces that it will host a conference call at 4:20 p.m., Eastern Time, on Friday, December 19, 2025, to discuss the company's September 30, 2025 fourth quarter and fiscal year 2025 financial results and business progress. CONFERENCE CALL DETAILS Friday, December 19, 2025, 4:20 p.m. Eastern Time USA/Canada: 888-880-3330 Webcast/Webcast Replay link - available through December 19, 2026: https://app.webinar.net/13voDmbBl

    12/17/25 7:16:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    $YCBD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by cbdMD Inc. (Amendment)

    SC 13D/A - cbdMD, Inc. (0001644903) (Subject)

    8/12/22 4:02:14 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form SC 13D/A filed by cbdMD Inc. (Amendment)

    SC 13D/A - cbdMD, Inc. (0001644903) (Subject)

    6/21/22 7:52:33 AM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form SC 13D/A filed by cbdMD Inc. (Amendment)

    SC 13D/A - cbdMD, Inc. (0001644903) (Subject)

    5/19/22 4:05:28 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary